688131.SHG Shanghai Haoyuan Chemexpress Co. Ltd. A
- Market cap
- CNY 21.5B
- P/E
- 61.5x
- P/B
- 5.58x
- ROE
- 12.0%
- Dividend yield
- 0.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688131.SHG undervalued?
Graham numberThe Graham number of Shanghai Haoyuan Chemexpress Co. Ltd. A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Haoyuan Chemexpress Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai Haoyuan Chemexpress Co. Ltd. A yet.
Shanghai Haoyuan Chemexpress Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. engages in the research, development, and manufacture of pharmaceutical intermediates and small molecule drugs. It offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.
Full company profileShanghai Haoyuan Chemexpress Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Haoyuan Chemexpress Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 117M | 174M | 300M | 409M | 635M | 969M | 1.36B | 1.88B | 2.27B | 2.87B | 3.53B |
| Gross Profit | 55.8M | 90.7M | 144M | 222M | 329M | 495M | 656M | 767M | 960M | 2.87B | 1.79B |
| Operating Income | 17.2M | 16.2M | 24.0M | 84.4M | 149M | 210M | 197M | 128M | 237M | 310M | 794M |
| EBITDA | 21.9M | 19.3M | 30.5M | 92.2M | 161M | 238M | 255M | 250M | 407M | 408M | 515M |
| Net Income | 18.0M | 15.0M | 18.4M | 73.4M | 128M | 191M | 194M | 127M | 202M | 248M | 412M |
| EPS | 0.85 | 0.08 | 0.15 | 0.50 | 0.84 | 1.07 | 0.95 | 0.61 | 0.96 | 1.17 | 1.93 |
| Balance Sheet | |||||||||||
| Total Assets | 156M | 192M | 304M | 542M | 857M | 2.38B | 3.60B | 4.19B | 5.50B | 6.29B | 6.91B |
| Total Liabilities | 99.3M | 76.9M | 127M | 143M | 329M | 548M | 1.27B | 1.67B | 2.60B | -3.13B | 3.45B |
| Shareholders' Equity | 56.0M | 115M | 178M | 400M | 528M | 1.82B | 2.32B | 2.51B | 2.88B | 3.13B | 3.44B |
| Cash & Short-term Investments | 53.0M | 49.7M | 80.0M | 203M | 292M | 1.04B | 477M | 484M | 1.33B | 1.47B | 1.66B |
| Total Debt | 20.0M | 20.0M | 38.2M | 24.0M | 76.9M | 197M | 646M | 953M | 1.79B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.2M | 10.6M | 28.4M | 57.1M | 117M | 57.8M | -240M | -62.3M | 382M | 318M | - |
| Capital Expenditure | 1.41M | 9.37M | 35.4M | 20.6M | 71.2M | 288M | 581M | 260M | 304M | 222M | 227M |
| Free Cash Flow | -13.6M | 1.26M | -7.00M | 36.5M | 45.6M | -230M | -822M | -323M | 77.5M | 96.0M | 167M |
| Ratios | |||||||||||
| ROE | 32.2% | 13.1% | 10.4% | 18.4% | 24.3% | 10.5% | 8.3% | 5.1% | 7.0% | 7.9% | 12.0% |
| ROA | 11.5% | 7.8% | 6.0% | 13.5% | 15.0% | 8.0% | 5.4% | 3.0% | 3.7% | 3.9% | 6.0% |
| Net Profit Margin | 15.4% | 8.6% | 6.1% | 18.0% | 20.2% | 19.7% | 14.3% | 6.8% | 8.9% | 8.6% | 11.7% |
| Debt to Equity | 0.36x | 0.17x | 0.22x | 0.06x | 0.15x | 0.11x | 0.28x | 0.38x | 0.62x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Haoyuan Chemexpress Co. Ltd. A dividends
- Dividend yield
- 0.36%
- Forward dividend
- 0.24 CNY
- Payout ratio
- 31.5%
- Ex-dividend date
- Sep 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 78.0M | 0.37 | 31.5% |
| 2024 | CNY 47.0M | 0.22 | 23.3% |
| 2023 | CNY 40.8M | 0.20 | 32.0% |
| 2022 | CNY 47.1M | 0.23 | 24.3% |
| 2021 | CNY 1.82M | 0.01 | 1.0% |
| 2020 | CNY 2.63M | 0.02 | 2.0% |
| 2019 | CNY 24.6M | 0.17 | 33.6% |
| 2018 | 3.04M | 0.02 | 16.5% |
| 2017 | 767K | 0.00 | 5.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 27, 2024.
Who owns Shanghai Haoyuan Chemexpress Co. Ltd. A
- Insiders 45.50%
- Institutions 10.30%
- Public & others 44.20%
- Shares outstanding 213M
- Free float 120M
Shanghai Haoyuan Chemexpress Co. Ltd. A company profile
- Company name
- Shanghai Haoyuan Chemexpress Co. Ltd. A
- Ticker
- 688131.SHG
- ISIN
- CNE1000051J4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,195
- Fiscal year end
- December
- Address
- No. 3 Building, Shanghai, China, 201203
- Phone
- 86 21 5899 8590
- Website
- chemexpress.cn
About Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. engages in the research, development, and manufacture of pharmaceutical intermediates and small molecule drugs. It offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.
Shanghai Haoyuan Chemexpress Co. Ltd. A management
7- Mr. Baofu ZhengChairman & GM · born 1979
- Ms. Min LiCFO & Accounting Supervisor · born 1981
- Mr. Qiang GaoDeputy GM & Director · born 1973
- Ms. Ying XuHead of Analyst & Director · born 1985
- Ms. Weihong ShenBoard Secretary · born 1986
- Mr. Zhiguo ZhouCore Technical Staff · born 1978
- Mr. Kuei MeiCore Technical Staff · born 1981